Medical/Pharmaceuticals
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a l...
2024-01-24 17:49
2032
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University. This P...
2024-01-24 16:50
2566
Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints
EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a firs...
2024-01-24 15:00
1498
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) ofthe United States to init...
2024-01-24 12:40
1735
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical...
2024-01-24 11:37
1532
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® * The clinical trial aims to enroll a total of 67 patients across four institutions inAustralia DAEJEON, South Korea, Jan. 23, 2024 /PRNewswire/ ...
2024-01-24 10:01
1347
Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide
* Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most commonly reported adverse events * Study participants receiving up to 30 mg oral ecnoglutide once-daily for 6 weeks achieved a mean body weight reduction of -6.8% from baseline, compared to -0.9% for...
2024-01-24 10:00
1802
INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness
Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts ROME and CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the devel...
2024-01-24 08:22
1487
Datasea Pre-Announces First Half 2024 Revenue of $18.2 Million, a 1,037.5% Year-Over-Year Increase
BEIJING, Jan. 23, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology inChina pre-announced that its revenue...
2024-01-23 22:35
3356
Rhino Rescue Speeds into the Future of First-Aid Supplies with New Year Resolutions for 2024
Propelling Lifesaving Measures with User-friendly Innovations in 2024
SHANGHAI, Jan. 23, 2024 /PRNewswire/ -- As the New Year unfolds, Rhino Rescue
2024-01-23 22:15
1818
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301) for subcutaneous fat reduction. "We are all delighted to see CBL-514 showing its ...
2024-01-23 21:12
1767
Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery
Collaboration aims to transform research to improve patient outcomes and enhance the understanding of ALS and motor neuron diseases (MND) MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life scien...
2024-01-23 21:03
1525
Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI
HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...
2024-01-23 21:00
3282
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514 show...
2024-01-23 18:35
1383
Baird Medical Performs First Thyroid Microwave Ablation Procedure in the United States
FRISCO, Texas, Jan. 23, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it has performed its first thyroid MWA procedure inthe United...
2024-01-23 18:00
1349
FDA Grants Breakthrough Device Designation to Amadix´s preventive screening blood test for Colorectal Cancer
* PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existing alternatives inthe United States. * Amadix becomes the first European company to announce this recognition for early detection of colorectal...
2024-01-23 18:00
2226
Apollo Cancer Centres launches India's 1st AI-Precision Oncology Centre
BENGALURU, India, Jan. 23, 2024 /PRNewswire/ -- In a significant move that will
substantially enhance the quality of oncology care,Apollo Cancer Centre
2024-01-23 16:27
1683
2024 Japan Prize Laureates Announced
TOKYO, Jan. 23, 2024 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2024 Japan prize onJanuary 23, 2024. Prof. Sir Brian J. Hoskins (UK) and Prof.John Michael Wallace (USA) are co-winners of the Japan Prize in the fields of Resources, Energy, the Environment, and Social I...
2024-01-23 14:00
749
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis - Primary efficacy endpoints: * NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD A...
2024-01-23 12:17
2432
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)
YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo Syndrome...
2024-01-23 11:53
1594
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00
Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 292 media titles]
2025-01-23 09:00
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
7768
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
5664
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4964
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
4801
